Sweden · Delayed Price · Currency is SEK OncoZenge AB Statistics
Total Valuation
OncoZenge AB has a market cap or net worth of SEK 62.58 million. The enterprise value is 69.33 million.
| Market Cap | 62.58M |
| Enterprise Value | 69.33M |
Important Dates
The last earnings date was Monday, August 31, 2026.
| Earnings Date | Aug 31, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
OncoZenge AB has 16.38 million shares outstanding. The number of shares has increased by 11.90% in one year.
| Current Share Class | 16.38M |
| Shares Outstanding | 16.38M |
| Shares Change (YoY) | +11.90% |
| Shares Change (QoQ) | +5.87% |
| Owned by Insiders (%) | 33.50% |
| Owned by Institutions (%) | 11.61% |
| Float | 7.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.48 |
| PB Ratio | 6.38 |
| P/TBV Ratio | 21.19 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 11.61 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.51, with a Debt / Equity ratio of 0.76.
| Current Ratio | 0.51 |
| Quick Ratio | 0.35 |
| Debt / Equity | 0.76 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.31 |
| Interest Coverage | -49.06 |
Financial Efficiency
Return on equity (ROE) is -231.25% and return on invested capital (ROIC) is -106.45%.
| Return on Equity (ROE) | -231.25% |
| Return on Assets (ROA) | -76.19% |
| Return on Invested Capital (ROIC) | -106.45% |
| Return on Capital Employed (ROCE) | -148.28% |
| Weighted Average Cost of Capital (WACC) | 10.79% |
| Revenue Per Employee | 5.97M |
| Profits Per Employee | -26.17M |
| Employee Count | 1 |
| Asset Turnover | 0.28 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -40.68% in the last 52 weeks. The beta is 1.30, so OncoZenge AB's price volatility has been higher than the market average.
| Beta (5Y) | 1.30 |
| 52-Week Price Change | -40.68% |
| 50-Day Moving Average | 6.34 |
| 200-Day Moving Average | 6.19 |
| Relative Strength Index (RSI) | 26.15 |
| Average Volume (20 Days) | 53,158 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, OncoZenge AB had revenue of SEK 5.97 million and -26.17 million in losses. Loss per share was -2.00.
| Revenue | 5.97M |
| Gross Profit | 5.97M |
| Operating Income | -25.66M |
| Pretax Income | -26.17M |
| Net Income | -26.17M |
| EBITDA | n/a |
| EBIT | -25.66M |
| Loss Per Share | -2.00 |
Balance Sheet
The company has 749,000 in cash and 7.50 million in debt, with a net cash position of -6.75 million or -0.41 per share.
| Cash & Cash Equivalents | 749,000 |
| Total Debt | 7.50M |
| Net Cash | -6.75M |
| Net Cash Per Share | -0.41 |
| Equity (Book Value) | 9.80M |
| Book Value Per Share | 0.70 |
| Working Capital | -4.65M |
Cash Flow
| Operating Cash Flow | -23.79M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | 9.50M |
| Free Cash Flow | -24.43M |
| FCF Per Share | -1.49 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -429.58% |
| Pretax Margin | -438.07% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OncoZenge AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.90% |
| Shareholder Yield | -11.90% |
| Earnings Yield | -41.81% |
| FCF Yield | -39.03% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
OncoZenge AB has an Altman Z-Score of -5.71 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.71 |
| Piotroski F-Score | 2 |